WUMC Cancer and Leukemia Group B

描述（申请人提供）：华盛顿大学自1986年以来一直是CALGB的主要成员机构。在过去的六年里，位于巴恩斯犹太医院和华盛顿大学医学院的Siteman癌症中心（SCC）已经发展成为全国领先的NCI癌症中心之一。2004年被指定为综合癌症中心，2006年被指定为国家综合癌症网络（NCCN）的第20个成员，Siteman加强了其合作和转化基础设施，这提高了华盛顿大学CALGB的科学能力。在上一个拨款周期中，3名华盛顿大学教员担任CALGB科学委员会主席，另有11名教员担任科学委员会委员。从2003年到2008年，WUMS教师主持了26项治疗和相关科学协议，并共同撰写了74篇CALGB出版物。在整个资助期间，威斯康星大学继续保持良好的增长势头，每年在CALGB机构中排名前五。在此拨款期间，所有CALGB试验的累积WUMS平均为293例/年，治疗试验的累积WUMS平均为140例/年。我们的投资组合保持多样化，在乳腺、Gl、GU、白血病和淋巴瘤研究方面表现优异。2007-2008年新聘的几位教员将进一步增强我们为CALGB科学使命做出贡献的能力，特别是在乳腺癌、药理学和实验治疗学、胸部肿瘤学、白血病和淋巴瘤领域。WUMS研究人员与CALGB白血病组织库之间正在进行合作，继续努力确定AML中的关键突变。下一个拨款周期的目标包括：1)继续努力增加应计费用，特别是CALGB试验的少数应计费用；2)增加WUMS研究人员在CALGB科学委员会（特别是白血病、PET、Gl和成像）中的参与；3)增加我们经验丰富和杰出的CRA在审计和CRA委员会中的参与；4)改善WUMS和CALGB之间关于SCC可用资源的沟通，这将增强SCC的有效性

DESCRIPTION (provided by applicant): Washington University has been a CALGB main member institution since 1986. Over the last six years, the Siteman Cancer Center (SCC) at Barnes-Jewish Hospital and Washington University School of Medicine (WUMS) has grown to become one of the leading NCI Cancer Centers nationally. Designated in 2004 as a Comprehensive Cancer Center and in 2006 as the 20th member of the National Comprehensive Cancer Network (NCCN), Siteman has enhanced its collaborative and translational infrastructure, which has increased the scientific capacity of the CALGB at Washington University. During the last grant cycle, 3 Washington University faculty members chaired CALGB scientific committees, and 11 additional faculty members served on scientific committees. From 2003-2008, WUMS faculty chaired 26 treatment and correlative science protocols and co-authored 74 CALGB publications. WUMS has continued to accrue well throughout the entire grant period, ranking in the top 5 among CALGB institutions every year. WUMS accrual to all CALGB trials during this grant period averaged 293/year with an average of 140 patients/year accrued to therapeutic trials. Our portfolio remains diverse with excellent accruals to breast, Gl, GU, leukemia and lymphoma studies. Several new faculty recruits in 2007-2008 will further enhance our ability to contribute to the CALGB scientific mission, specifically in the areas of breast cancer, pharmacology and experimental therapeutics, thoracic oncology, leukemia, and lymphoma. Collaborations are ongoing between WUMS investigators and the CALGB leukemia tissue bank, with continued efforts to identify key mutations in AML. Goals for the next grant cycle include 1) continued efforts to increase accruals, particularly minority accruals to CALGB trials, 2) increased involvement of WUMS investigators in CALGB scientific committees specifically leukemia, PET, Gl, and imaging 3) increased involvement of our very experienced and outstanding CRAs in the audit and CRA committees, and 4) improved communication between WUMS and CALGB regarding resources available at the SCC that will enhance the